For unresectable, metastatic or advanced thyroid cancer, pan-TRK IHC screening is recommended to be performed on all cases followed by NGS testing for NTRK to confirm IHC positive and equivocal cases [53]. The gene discussed is NTRK1; the disease is thyroid cancer.